Bessemer Group’s Akero Therapeutics AKRO Stock Holding History

Bessemer Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-194	Closed	-$10K	–	2518
2025 Q3	$10K	Buy	194 +96	+98%	+$4.65K	﹤0.01%	1929
2025 Q2	$5K	Hold	98	–	–	﹤0.01%	2000
2025 Q1	$4K	Buy	98 +38	+63%	+$1.61K	﹤0.01%	2059
2024 Q4	$2K	Hold	60	–	–	﹤0.01%	2178
2024 Q3	$2K	Buy	+60	New	+$1.56K	﹤0.01%	2152
2022 Q2	–	Sell	-203	Closed	-$3K	–	1860
2022 Q1	$3K	Hold	203	–	–	﹤0.01%	1661
2021 Q4	$4K	Hold	203	–	–	﹤0.01%	1615
2021 Q3	$5K	Hold	203	–	–	﹤0.01%	1498
2021 Q2	$5K	Hold	203	–	–	﹤0.01%	1423
2021 Q1	$6K	Buy	+203	New	+$6.14K	﹤0.01%	1366

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bessemer Group's AKRO Position: Q4 2025 in Review

Bessemer Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 194 shares — an estimated $10K sold.

Bessemer Group first reported a position in AKRO in Q1 2021 and held it in 10 quarters. The position peaked at $10K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Bessemer Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Bessemer Group sold 194 Akero Therapeutics shares in Q4 2025, an estimated $10K.
Bessemer Group first reported a position in Akero Therapeutics in Q1 2021 and held it in 10 quarters.
Bessemer Group's Akero Therapeutics position peaked at $10K in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.